ライフサイエンスコーパス: activated platelet

1 latelet, but remodels and centralizes in the activated platelet.

2 was overlaid with an unstable shell of less-activated platelets.

3 produced by megakaryocytes and released from activated platelets.

4 ndicating the release of certain miRNAs from activated platelets.

5 from 0.8 to 2.1% (p < 0.001) on addition of activated platelets.

6 te in a nanoparticle state on the surface of activated platelets.

7 ed A11) capable of inducing fragmentation of activated platelets.

8 ytoskeletons isolated from either resting or activated platelets.

9 the surface of either thrombin- or collagen-activated platelets.

10 associated only with actin cytoskeletons of activated platelets.

11 CD40L), a proinflammatory marker released by activated platelets.

12 ASp-interacting protein (WIP) in resting and activated platelets.

13 ed a catalog of the components released from activated platelets.

14 ted the coating of quiescent leukocytes with activated platelets.

15 microparticles, but not microparticles from activated platelets.

16 were found only on mouse microparticles from activated platelets.

17 with functional receptors on the surface of activated platelets.

18 e effectively by C1C2 than C2 for binding to activated platelets.

19 ar subdomain within factor XIa that binds to activated platelets.

20 amount of NO released from stimulated and/or activated platelets.

21 otential (Deltapsi(m)) in a subpopulation of activated platelets.

22 nt for endothelial cells that is released by activated platelets.

23 me mainly from studies of a subpopulation of activated platelets.

24 1 signaling prevents TF from accumulating in activated platelets.

25 Xa), and factor XIa complexes on PS-exposed activated platelets.

26 bundled agglomerates tightly associated with activated platelets.

27 on system can be localized to the surface of activated platelets.

28 ich repeats, inhibited the binding of FXI to activated platelets.

29 of factor IX and IXa to thrombin- or SFLLRN-activated platelets.

30 site had no effect on the binding of FXI to activated platelets.

31 nase complex on the surfaces of vesicles and activated platelets.

32 referentially to adenosine diphosphate (ADP)-activated platelets.

33 a antagonists inhibit release of sCD40L from activated platelets.

34 sembly of the factor X-activating complex on activated platelets.

35 ellular localization of PIP5K in resting and activated platelets.

36 e-rich repeats on the binding of 125I-FXI to activated platelets.

37 cule expressed on both endothelial cells and activated platelets.

38 lyzed by either casein kinase II or thrombin-activated platelets.

39 to a high-affinity, low-capacity receptor on activated platelets.

40 the main receptor for Efb on the surface of activated platelets.

41 organization of granules in unstimulated and activated platelets.

42 p in generating soluble EGF bioactivity from activated platelets.

43 were massively infiltrated by aggregates of activated platelets.

44 d fibrinolytic drug that is directed against activated platelets.

45 ated platelets is covered by a shell of less-activated platelets.

46 at has recently been shown to be secreted by activated platelets.

47 GDV) that binds with GPIIb/IIIa expressed on activated platelets.

48 binding affinity of camouflaged tPA with the activated platelets.

49 n released by activated neutrophils binds to activated platelets.

50 ighlighted a role for secreted product(s) of activated platelets.

51 permitting storage and release of FVIII from activated platelets.

52 ts can be uncoupled from monocyte binding to activated platelets.

53 hat, for optimal function in the presence of activated platelets, a preformed dimer of factor XI is n

54 ibution from enhanced levels of thrombin and activated platelets, a synergistic consequence of an Fg

55 Following EV injection, activated platelets accumulate particularly within the p

56 Activated platelets adhere to intravascular neutrophils

57 Activated platelets adhered were and ultimately digested

58 Activated platelets adherent to adsorbed mutant fibrinog

59 soluble fibronectin by lysophosphatidic acid-activated platelets adherent to fibrinogen or fibrin.

60 Many of these gaps contain activated platelets adhering to exposed basement membran

61 a Kunitz-type protease inhibitor secreted by activated platelets and a physiologically important inhi

62 icellular protein released in abundance from activated platelets and accumulated in sites of vascular

63 lymer of inorganic phosphate, is secreted by activated platelets and accumulates in many infectious m

64 RBC adhesion to activated platelets and activated neutrophils was preven

65 actor Xa generation assay in the presence of activated platelets and cofactor factor VIIIa, compared

66 QGAP2 expression in filopodial extensions of activated platelets and colocalized with F-actin in lame

67 verexpressed 1 (CCN1) protein is released by activated platelets and enables the recruitment of Ly6C(

68 Leukocyte adhesion to P-selectin on activated platelets and endothelial cells induces sheddi

69 a member of the selectin family expressed by activated platelets and endothelium, contributed to both

70 iates the initial tethering of leukocytes to activated platelets and endothelium.

71 und to albumin and is reported to arise from activated platelets and erythrocytes.

72 Polyphosphate (polyP) is secreted by activated platelets and has been shown to contribute to

73 CXCL4 is a chemokine abundantly produced by activated platelets and immune cells.

74 al, as well as being a substance released by activated platelets and injured cells.

75 es human alphaIIbbeta3 on both quiescent and activated platelets and is enzymatically activated speci

76 and TLR4 with mAbs reduced the percentage of activated platelets and lowered the amount of thrombin g

77 ein thrombospondin-1 (hTSP-1) is released by activated platelets and mediates adhesion of Gram-positi

78 Polyphosphate (polyP) is released from activated platelets and mediates FXII activation.

79 rol MBs strongly adhered to both immobilized activated platelets and microthrombi under flow.

80 rgeted to the negatively charged surfaces of activated platelets and other cells, where it can serve

81 CF patients have an increase in circulating activated platelets and platelet reactivity, as determin

82 Recent studies have suggested that activated platelets and platelet thrombi can contribute

83 We studied whether circulating activated platelets and platelet-leukocyte aggregates ca

84 The presence of activated platelets and platelet-leukocyte aggregates in

85 Activated platelets and platelet-leukocyte aggregates in

86 LIPRs are formed downstream the adherent and activated platelets and reach lengths of 250 mum.

87 The combination of activated platelets and specific immunoglobulin G-adsorb

88 We prospectively determined whether activated platelets and systemic procoagulant factors we

89 ARCKS) bind to phosphatidylserine exposed on activated platelets and thereby inhibit fibrin formation

90 elevation, share a common pathophysiology of activated platelets and thrombin generation stimulated b

91 nvestigate a possible release of miRNAs from activated platelets and to elucidate whether platelet-de

92 P-selectin expressed on activated platelets and vascular endothelium mediates ad

93 h antibodies against neutrophils, platelets, activated platelets, and endothelium.

94 the TREM family, is selectively expressed on activated platelets, and is known to facilitate platelet

95 factor of serum is LPA generated by thrombin-activated platelets, and media from activated platelets

96 The released material activated platelets, and platelets co-aggregated with en

97 Microvesicles bound only activated platelets, and required PSGL-1 to do so.

98 s reveal that recruited neutrophils scan for activated platelets, and they suggest that the neutrophi

99 in vitro to selectin-coated dishes, thrombin-activated platelets, and tumor necrosis factor alpha-act

100 C1C2 binding to activated platelets appeared independent of von Willebra

101 at factor XI was localized to lipid rafts in activated platelets ( approximately 8% of total bound) b

102 Activated platelets are considered to provide the primar

103 Recent findings indicate that the activated platelets are crucial regulators of tumor vasc

104 glycoprotein (GP) IIb/IIIa on the surface of activated platelets are degraded by the serine protease

105 Activated platelets are known to modulate immune respons

106 ane-bound protease complex on the surface of activated platelets at the site of a vascular injury.

107 We report that thrombin-activated platelets, at physiologic concentration and pH

108 More than 90% of activated platelets bound C1C2, compared with approximat

109 wn that the zymogen factor XI (FXI) binds to activated platelets but not to human umbilical vein endo

110 hed FXI binding to HUVECs in the presence of activated platelets, but FXI did not influence PK bindin

111 These results support the concept that activated platelets, but not endothelial cells, expose a

112 ression was assessed in resting and thrombin-activated platelets by flow cytometry and in mucosal mic

113 esults suggest that PS-mediated clearance of activated platelets by the endothelium results in an ant

114 imize the procoagulant activity expressed by activated platelets, by limiting the anticoagulant funct

115 per, we show that the converse is also true: activated platelets can activate the complement system.

116 Activated platelets can activate the complement system.

117 Activated platelets can also supply the sialic acid dono

118 timulate platelet production and activation; activated platelets can, in turn, promote tumor growth a

119 noids such as thromboxane A2 Releasates from activated platelets caused cell migration and tube forma

120 Elevated numbers of activated platelets circulate in patients with chronic i

121 es and all C5a-stimulated monocytes (but not activated platelets) completely convert factor VII to fa

122 b/beta3 integrin) receptor on the surface of activated platelets constitutes the common pathway for p

123 Thus, activated platelets contribute to CTL-mediated liver imm

124 Recent findings that activated platelets contribute to the inflammatory disea

125 We hypothesized that activated platelets could also release their mitochondri

126 -3 is required for condensation of fibrin by activated platelets, demonstrating functional significan

127 mammalian Nck adaptors in signaling from the activated platelet-derived growth factor (PDGF) receptor

128 1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-alpha

129 activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor.

130 Activated platelets display immobilized fibrinogen on th

131 inds to the glycoprotein IIb/IIIa present on activated platelets (DMP-444).

132 by thrombin in solution or on the surface of activated platelets does not appear to play a significan

133 xA(2)) is one of the mediators released from activated platelets during myocardial ischaemia.

134 on assay both in the presence and absence of activated platelets even at concentrations at which less

135 Activated platelets expose phosphatidylserine on their o

136 The recent demonstration that activated platelets express CD40 ligand (L) provides a m

137 In cadaver allografts with deposition of activated platelets expressing either P-selectin or vWF,

138 hosphatidylserine (PS)-exposing procoagulant-activated platelets followed by formation of the membran

139 We analyzed GPVI-activated platelets from ST-elevation myocardial infarct

140 ptor alphaIIbbeta3, was observed in thrombin-activated platelets from wild-type but not Gpx1 Tg mice

141 sence of low ADP levels, HMEC-1 supernatants activated platelet function assessed by classical aggreg

142 n of fluid shear to whole blood, half of the activated platelets had DeltaA1-488 bound, suggesting th

143 neoantigen on glycoprotein IIIa expressed on activated platelets, had significant inhibitory effects

144 Prothrombinase assembled on the surface of activated platelets has been shown to proceed through th

145 Our findings suggest that activated platelets have anti-inflammatory properties re

146 GD is unclear, although both neutrophils and activated platelets have been implicated.

147 Proteomic experiments in resting and activated platelets have identified novel signaling path

148 Activated platelets have key thromboinflammatory activit

149 With activated platelets having mutual tensile action sustain

150 ed well only to GFOGER and GLOGER, while ADP-activated platelets, HT1080 cells and two active alpha(2

151 etting of hyperlipidemia and atherosclerosis activated platelets in a CD36-dependent manner.

152 ulated neutrophils avidly bound Ps-beads and activated platelets in an integrin-independent manner, s

153 hese monocyte-derived microparticles bind to activated platelets in an interaction mediated by platel

154 venues that might help elucidate the role of activated platelets in CF.

155 We conclude that the presence of activated platelets in circulation promotes acute inflam

156 The mechanisms that eliminate activated platelets in inflammation-induced disseminated

157 bility group box 1 (HMGB1) is upregulated by activated platelets in multiple inflammatory diseases; h

158 Ibalpha were able to inhibit FXI binding to activated platelets in the following order of decreasing

159 des circulate to remote injuries and bind to activated platelets in the inner core of developing thro

160 d to anionic phospholipids on the surface of activated platelets in the presence of calcium ions.

161 ,744), showed heparin-dependent binding, and activated platelets in the presence of protamine.

162 n IIb/IIIa-targeted MBs specifically bind to activated platelets in vitro and allow real-time molecul

163 monoclonal anti-CD40L immune complexes (ICs) activated platelets in vitro via the IgG receptor (Fcgam

164 ticles--submicrometer vesicles elaborated by activated platelets--in joint fluid from patients with r

165 megakaryocytes (MKs) with the releasate from activated platelets increased proplatelet production by

166 These findings demonstrate that activated platelets induce COX-2 synthesis in monocytes

167 Here, we report that activated platelets induce the formation of neutrophil e

168 Conditioned medium from activated platelets induced an IL-1alpha-dependent activ

169 Activated platelets induced endothelial expression of IC

170 eby protects mitochondrial function, reduces activated platelet-induced mitochondrial hyperpolarizati

171 arterial thrombosis and protect animals from activated platelet-induced venous thromboembolism withou

172 eport that coculture of human monocytes with activated platelets induces phosphorylation of Akt, toge

173 lectin, a key adhesion molecule displayed by activated platelets, induces NF-kappaB activation and CO

174 ine 1-phosphate (S1P), a lipid released from activated platelets, influences physiological processes

175 In addition, activated platelets inhibited CD4(+) T cell proliferatio

176 The i.v. injection of thrombin-activated platelets into CD40(-/-)apoE(-/-) mice was per

177 Infusion of activated platelets into young mice led to the formation

178 on, suggesting that the NO production in the activated platelet is due to ATP.

179 istic architecture in which a core of highly activated platelets is covered by a shell of less-activa

180 ion of an inflammatory monocyte phenotype by activated platelets is implicated in the pathogenesis of

181 moieties released from the dense granules of activated platelets, is a procoagulant agent.

182 splaced [125I]factor XIa from the surface of activated platelets (Ki approximately 5.8 nM), whereas a

183 was able to compete with FXI for binding to activated platelets (Ki of 3.125 +/- 0.25 nm) with a pot

184 sults in the formation of a subpopulation of activated platelets known as coated platelets.

185 Although low-tar mainstream extracts activated platelets less than high-tar extracts, the sid

186 infectious microorganisms and is secreted by activated platelets; long-chain polyphosphate in particu

187 Activated platelets made IL-1beta in vivo as IL-1beta ra

188 Thus, targeting of activated platelets may allow for molecular imaging of v

189 suggest that binding of autotaxin/lysoPLD to activated platelets may provide a mechanism to localize

190 lyP and FXII were found to colocalize on the activated platelet membrane in a fibrin-dependent manner

191 for platelet FXIII-A through exposure on the activated platelet membrane where it exerts antifibrinol

192 in the FVIIIa-FIXa complex assembled on the activated platelet membrane.

193 possible role of platelet microparticles or activated platelet membranes, which carry a negative cha

194 Released Zn2+ from 2-8 x 10(8) collagen-activated platelets/ml supported biotin-FXI binding to H

195 HIT is propagated by activated platelets, monocytes, endothelial cells, and c

196 Activation of the alternative pathway on activated platelets occurs when properdin is on the surf

197 We examined the influence of activated platelets on cytokine production by normal hum

198 r actomyosin rearrangements and spreading of activated platelets on fibrinogen.

199 er demonstrate that the secondary capture of activated platelets on the plaque is predominantly media

200 donors, whereas microparticles derived from activated platelets only express CLEC-2.

201 ichiometry and affinity of FVIIIa binding to activated platelets only in the presence of FIXa and FX

202 Consistent with observed mRNA stabilization, activated platelets or IL-1beta treatment induced cytopl

203 Release of polyphosphate from activated platelets or infectious microorganisms may pla

204 ng microparticles are derived primarily from activated platelets or megakaryocytes, we identified mar

205 titrating factor X or factor VIIIa on SFLLRN-activated platelets or phospholipid vesicles revealed ne

206 PS was phosphorylated on exposure to activated platelets or their releasates, as judged by im

207 ascade by parasitized red blood cells and/or activated platelets (particularly at sequestration sites

208 complexes between inflammatory monocytes and activated platelets (PMCs), which are detected by flow c

209 These data show that histone-activated platelets possess a procoagulant phenotype tha

210 Pyrophosphate, which is also secreted by activated platelets, potently blocked polyphosphate-medi

211 to organize a protruding domain that engaged activated platelets present in the bloodstream.

212 Activated platelets promote cancer progression and metas

213 Activated platelets promote intrinsic factor X-activatin

214 Activated platelets provide a promising target for imagi

215 Activated platelets provide a surface for assembly of th

216 Thus, delayed targeting of CD39 via scFv to activated platelets provides strong antithrombotic poten

217 entification of novel signaling molecules in activated platelets, providing new insights into the mec

218 In vitro, LPS-activated platelets rather than LPS alone efficiently in

219 (FIXa), factor VIII(a) [FVIII(a)], and FX to activated platelet receptors.

220 ed with either serum, DBP-depleted serum, or activated platelet releasate provides a required factor

221 Fractionation of activated platelet releasate revealed that the additiona

222 We conclude that activated platelets release ADAMDEC1, which hydrolyzes p

223 We now show that activated platelets release glutamate, that platelets ex

224 Activated platelets release many inflammatory molecules

225 We show that activated platelets release respiratory-competent mitoch

226 Activated platelets release their granule content in a c

227 Activated platelets released high-molecular-weight (HMW)

228 Many of the cellular responses that occur in activated platelets resemble events that take place foll

229 Likewise, only thrombin-activated platelets resulted in rapid translocation of I

230 nfocal and electron microscopy, we show that activated platelets retain polyphosphate on their cell s

231 formation (NETosis) was induced by thrombin-activated platelets rosetting with neutrophils and was i

232 Activated platelets secrete a negatively charged polymer

233 Activated platelets secrete platelet-derived growth fact

234 Activated platelets secrete the highly anionic polymer p

235 with MI exhibit loss of specific miRNAs, and activated platelets shed miRNAs that can regulate endoth

236 Activated platelets shed surface proteins, potentially m

237 More fibronectin was assembled by activated platelets spread on fibrin matrices than by pl

238 band likely function during both resting and activated platelet states.

239 Previous studies have shown that activated platelets stimulate ischaemically sensitive ca

240 lerosis made us address the question whether activated platelets stimulate normal healthy endothelium

241 thrombin-activated platelets, and media from activated platelets stimulated PPARgamma function in tra

242 cent studies have revealed that at least two activated platelet subpopulations are formed upon potent

243 Here, we demonstrate in vitro that activated platelets substantially inhibit recruitment of

244 domain significantly impaired Efb binding by activated platelets, suggesting that P-selectin is the m

245 d with [125I]factor XIa for binding sites on activated platelets, suggesting that the factor XIa bind

246 ent externalization of phosphatidylserine in activated platelets, suggesting that this homologue migh

247 ion studies and incubation of monocytes with activated platelet supernatant highlighted a role for se

248 that APC binds human leukocytes and prevents activated platelet supernatant or phorbol 12-myristate 1

249 latelet activation was assessed by measuring activated platelet surface expression of P-selectin and

250 m of the FVIIIa-FIXa complex assembly on the activated platelet surface in the propagation phase of b

251 y the presence of surfaces; however only the activated platelet surface protected FXIa from inhibitio

252 formed when prothrombin is processed on the activated platelet surface, the cleavage of prothrombin,

253 omplex of factors Va and Xa assembled on the activated platelet surface, which cleaves prothrombin at

254 ens the initial prothrombinase formed on the activated platelet surface.

255 fragment, the most relevant of which is the activated platelet surface.

256 purified plasma-derived FVa on the thrombin-activated platelet surface.

257 2" domain is responsible for binding to both activated platelet surfaces and von Willebrand factor.

258 a on negatively charged membranes, including activated platelet surfaces.

259 d by natural killer (NK) cells as well as by activated platelets that express CD40L.

260 Activated platelets that expressed P-selectin attached t

261 on and signal-dependant protein synthesis in activated platelets that may contribute to thrombus and

262 In ITAM-activated platelets that were treated with a PI3K inhibi

263 The microvesicles not only bound the activated platelets, they fused with them, transferring

264 identified in cellular SNAP-23 isolated from activated platelets; three phosphopeptides co-migrated w

265 crophage-derived microvesicles that can bind activated platelets through a mechanism involving P-sele

266 llograft rejection can thus be instigated by activated platelets through CD154.

267 modulation of monocyte cytokine responses by activated platelets through P-selectin binding, we found

268 The ability of activated platelets to adhere to each other at sites of

269 labeled miRNA and exogenous cel-miR-39 from activated platelets to endothelial cells was shown.

270 nfer that platelet activation and binding of activated platelets to eosinophils followed by P-selecti

271 ists, contribution of thrombin generation by activated platelets to the test results, and establishme

272 lot retraction refers to the process whereby activated platelets transduce contractile forces onto th

273 activity was tested on thrombin- and SFLLRN-activated platelets treated with RO318220, a potent inhi

274 pathway-inhibited blood or plasma containing activated platelets, typically no clot is observed for 2

275 a promising strategy to support adhesion to activated platelets under arterial shear stress, these a

276 is necessary for stable bacterial binding to activated platelets under shear.

277 The tube surface is resistant to adhesion of activated platelets unlike planar control titania and sm

278 Activated platelets up-regulated expression of intercell

279 CD41 microparticles also form from activated platelets upon loss of cytoskeleton-membrane a

280 By analyzing basal and TRAP-activated platelets using 2-dimensional gel electrophore

281 Evaluation of SNARE protein localization in activated platelets using immunonanogold staining and el

282 lyzing protein fragments in the supernate of activated platelets using mass spectroscopy and looking

283 Release of sCD40L from activated platelets was also markedly reduced in Glanzma

284 lease of Weibel-Palade bodies on infusion of activated platelets was indicated by both elevation of p

285 wever, release of sCD40L from the surface of activated platelets was inhibited by GP IIb/IIIa antagon

286 In contrast, shedding of P-selectin from activated platelets was not affected by the mutation in

287 organized structure in which a core of fully activated platelets was overlaid with an unstable shell

288 FXIII-A activity on activated platelets was unstable and was rapidly lost ov

289 emarkably, all these inflammatory actions by activated platelets were abrogated by lack of CD40 on in

290 Activated platelets were detectable by magnetic resonanc

291 (125)I-factor X and (131)I-factor VIII(a) to activated platelets were determined as a function of tim

292 rates of factor XI activation by thrombin on activated platelets were inhibited >85%.

293 Activated platelets were targeted with a contrast agent

294 Factor XI binds to activated platelets where it is efficiently activated by

295 regates involved the interaction of CD62P on activated platelets with adhesion molecule CD166 on acti

296 in micelles that can be targeted to sites of activated platelets with broad potential for treatment o

297 ably, assembly of FXa(I16L) and FXa(V17A) on activated platelets with factor Va to form prothrombinas

298 ificantly increases complement deposition on activated platelets with surface properdin.

299 l proteomic analysis of basal and rhodocytin-activated platelets with the aim of providing novel clue

300 h microbubbles (MBs) selectively targeted to activated platelets would offer high-resolution, real-ti